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Purpose. In this study, we evaluated our experience with salvage brachytherapy after discovery of biochemical recurrence after a
prior brachytherapy procedure. Methods and Materials. From 2001 through 2012 twenty-one patients treated by brachytherapy
within University of Kentucky or from outside centers developed biochemical failure and had no evidence of metastases.
Computed tomography (CT) scans were evaluated; patients who had an underseeded portion of their prostate were considered for
reimplantation. Results. Themajority of the patients in this study (61.9%) were low risk andmedian presalvage PSA was 3.49 (range
17.41–1.68). Mean follow-up was 61 months. At last follow-up after reseeding, 11/21 (52.4%) were free of biochemical recurrence.
There was a trend towards decreased freedom from biochemical recurrence in low risk patients (𝑝 = 0.12). International Prostate
Symptom Scores (IPSS) increased at 3-month follow-up visits but decreased and were equivalent to baseline scores at 18 months.
Conclusions. Salvage brachytherapy after primary brachytherapy is possible; however, in our experience the side-effect profile
after the second brachytherapy procedure was higher than after the first brachytherapy procedure. In this cohort of patients we
demonstrate that approximately 50% oncologic control, low risk patients appear to have better outcomes than others.
1. Introduction
The use of interstitial brachytherapy with permanent seed
implantation is a well-established means of treating localized
prostate cancer [1, 2]. Permanent interstitial brachyther-
apy for prostate cancer patients involves the insertion of
radioactive seeds (containing 125I, 103Pd, or 131Cs), encased
in titanium shells, into the prostate gland. Benefits of this
treatment modality include a single procedure rather than
weeks of daily external beam radiation therapy (EBRT) and
equivalent oncologic control for low and intermediate risk
disease [1]. Other studies have shown superior quality of
life regarding sexual function and urinary bother scores for
prostate seed implant compared to prostatectomy [3].
Unfortunately, up to as high as 10% to 15% of men
may experience prostate-specific antigen (PSA) failure in
five to ten years after interstitial brachytherapy for clinically
localized prostate cancer [2, 4]. Some of these men will
harbor a component of micrometastatic disease at the time of
PSA failure, but a significant number will have a true local-
only recurrence and potentially can be cured with a salvage
local therapy. Currently, there is no consensus regarding
the optimal management of patients who are believed to
have a local-only recurrence after prostate radiotherapy.
Palliativemanagement options include androgen deprivation
therapy or expectant management. A number of salvage
therapies with curative intent have also been assessed includ-
ing cryotherapy, EBRT, high-intensity focused ultrasound
(HIFU), brachytherapy, and radical prostatectomy [5, 6].
Data on salvage brachytherapy after primary brachyther-
apy is extremely limited. Much of the data in the current
literature comes from patients that were included in cohorts
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of patients treated with primary radiation therapy with the
majority of patients undergoing EBRT. To our knowledge,
there are only 2 studies that evaluate salvage brachytherapy
for patientswhowere initially treatedwith brachytherapy, one
in 1990 [7] in the pre-PSA era and one in 2003 [8]. In this
single center review of 21 patients, we describe our experience
with salvage brachytherapy for prostate cancer patients with
biochemical recurrence after primary brachytherapy focus-
ing on oncologic and functional outcomes.
2. Methods and Materials
From July 2001 until February 2012, we reviewed the records
of all patients who underwent salvage reimplantation at
our center. During this time frame 21 patients underwent a
repeat brachytherapy procedure. Of the 21 patients in this
analysis, 3 had a biopsy before the repeat brachytherapy
procedure and the remainder did not. Of these 21 patients, 14
had their initial brachytherapy procedure performed at the
University of Kentucky (UK). One of the patients initially
treated at UK was found to have poor coverage at the one-
month postimplant CT evaluation and subsequently had
a planned reimplantation. The other 13 patients initially
treated at UK had adequate postimplant dosimetry; years
later they developed a rising PSA. The remaining 7 men
in this cohort had their initial brachytherapy procedure
at other institutions. One of these 7 patients underwent
open brachytherapy procedure in 1984 and many years later
developed a rising PSA. Thus, of the patients in this cohort
20 of 21 patients had an acceptable brachytherapy procedure
and were later identified as having a biochemical failure
defined by either the ASTRO criteria or Phoenix criteria [9].
D’Amico criteria were used to stratify risk category [10]. All
patients who met the criteria for biochemical failure had a
bone scan and a computed tomography (CT) scan of the
abdomen and pelvis to rule out evidence of metastasis. The
pelvic CT scan was also evaluated by radiation oncology
and urology faculty to assess brachytherapy seed placement
within the prostate. If both radiation oncology and urology
faculty clinically agreed that a 3-dimensional volume of the
prostate was underseeded from the initial brachytherapy
procedure and the scans revealed no evidence of metastases,
those patients were considered for a brachytherapy salvage
procedure. If the prostate appeared to be well seeded with
no gaps or evidence of metastasis the patient was excluded
from a second brachytherapy procedure.There were no other
exclusion criteria, with no restrictions on presalvage PSA or
International Prostate Symptom Score (IPSS) survey results.
A preplanning TRUS volume study was performed, and
target volumes were outlined by a radiation oncologist
with urology collaboration. The target volume to receive
radioactive seeds only included the underseeded portion of
the prostate with a small margin, of 2mm. In addition, care
was taken to keep the urethral doses low; our goal was to
keep the urethral dose to no more than that of the prescribed
dose. BrachyVision software was utilized for brachytherapy
planning. Sample planning scans are shown in Figure 1(a). All
patients were treated using 125I seeds, and the prescribed dose
ranged from 108Gy to 144Gy (Table 1). When the dosimetric
plan was completed, stranded seeds were purchased from
a vendor (IsoAid) and the patient returned for implant in
approximately 2 weeks.
Epidural anesthesia was administered and patients were
placed in the dorsal lithotomy position. A urethral catheter
was inserted and instilled with ultrasonic contrast (surgical
lubricant with air bubbles) to visualize the urethra. A TRUS
probe was placed into the rectum, and the ultrasound images
were matched to the preplanned images acquired in the same
manner. When the real-time images of the prostate matched
the preplan images, the needles carrying the radioactive
seeds were inserted and the seeds were placed. Representative
postoperative CT images showing seed distribution after
reimplantation with and without reimplant isodose distribu-
tions are shown in Figure 1(b).
Androgen deprivation therapy (ADT) was concurrently
administered at the discretion of the treating physician.
Three of 21 (14.3%) patients received one 3-month injection
of Lupron along with their salvage brachytherapy. Two of
these patients ultimately had biochemical failure after their
reseeding.
Patients were followed up in a multidisciplinary urologic
oncology clinic by both urology and radiation oncology fac-
ulty. PSA values were obtained and patients were questioned
regarding potential treatment related toxicity. Lower urinary
tract symptoms were evaluated and categorized by their IPSS,
which were self-reported by the patients immediately prior
to each appointment. Patients were also questioned about
gastrointestinal complaints and other concerns and scored
according to the RTOG acute and late toxicity criteria.
Summary statistics such as median and range values
were calculated for patient characteristics and disease out-
comes. Kaplan-Meier curves andWilcoxon tests were used to
evaluate the association between time to biomedical failure
and patient categorical characteristics. Paired two-sample
𝑡-tests were used to determine the statistical significance
of differences in a continuous variable between two dif-
ferent measurement times. Fisher’s exact tests were used
to determine the statistical significance of differences in
binary outcomes between two patient groups. Significance
was considered using a two-sided 𝑝 value <0.05. Statistics
were carried out using Microsoft Excel, SAS version 9.2, and
R version 3.0.1.
3. Results
Radiation dosing utilized for the salvage therapy in this
study is summarized in Table 1. At initial diagnosis of
patients in this study, 3 of 21 (14.3%) patients received EBRT
with their initial brachytherapy. One of 21 (4.7%) patients
underwent open brachytherapy seed placement as his initial
brachytherapy. Risk categories were determined based on
initial PSA, Gleason score, and initial clinical stage. Thirteen
of 21 (61.3%) patients were low risk, and 6 of 21 (28.6%)
patients were intermediate risk; 7of 21 (33.3%) patients had
initial brachytherapy at other institutions and had incomplete
information to adequately calculate their risk category.
Mean presalvage PSA was 3.49 (median 3.6, range 17.41–
1.68). PSA dynamics for individual patients during the study
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Figure 1: (a) Sample brachytherapy planning scans usingBrachyVision software. (b)CT images showing seed distribution after reimplantation
with and without reimplant isodose distributions.
are shown in Table 2.Mean follow-upwas 61months.Median
nadir was 0.7 ng/mL (range 2.97–0.01 ng/mL) and median
time to nadir was 15 months. All men undergoing a salvage
brachytherapy procedure demonstrated an initial decline
in their serum PSA. Median time to biochemical failure
(according to the Phoenix criteria) of the men failing the
second implant was 25 months (range 11–71 months).
3.1. Toxicity. A few patients experienced adverse outcomes
following salvage brachytherapy during our study period.
4 Prostate Cancer
Table 1: Radiation dosing.
Patient # Age at initialtreatment (yr)
Prostate cancer
risk strata@
ADT with
BRT #1
ADT with
BRT #2 Initial dose
Time b/w Rx
(mo) Salvage dose Volume treated (cc)
1 ̸= 57 Low No No 115Gy 38 144Gy 21.55
2 61 Low No No 144Gy 32 144Gy 13.23
3 65 Low No Yes 144Gy 26 144Gy 7.56
4 63 Intermediate No No 144Gy 34 144Gy 9.98
5 59 Low No No 144Gy 26 108Gy 21.58
6 ̸= 50 Low No Yes 115Gy 67 108Gy 26.66
7 48 x No No x 287 108Gy 21.31
8 60 Low No No 144Gy 123 108Gy 6.84
9 55 Low Yes No 144Gy 120 108Gy 7.76
10 57 Low No No 144Gy 19 120Gy 23.78
11 48 Low Yes No 144Gy 25 125Gy 16.03
12 66 Low No No 144Gy 46 108Gy 18.16
13 44 Low No No 144Gy 31 144Gy 12.05
14 50 Intermediate No No 144Gy 87 144Gy 15.51
15∗ 66 Intermediate Yes No 108Gy 42 108Gy 8.1
16 71 Intermediate No No 144Gy 45 108Gy 29.36
17∗ 63 Intermediate No Yes 108Gy 48 108Gy 9.74
18∗∗ 42 x Yes No x 50 120Gy 12.94
19∗ 58 Intermediate Yes No 108Gy 105 108Gy 8.67
20 59 Low Yes No 144Gy 48 144Gy 27.31
21 72 Low Yes No 140Gy 21 140Gy 19.93
∗Patients who underwent initial external beam radiation therapy.
∗∗Patients who underwent initial open brachytherapy.
̸=Patients who had palladium-103 seeds for initial brachytherapy.
x = data point not known.
ADT = androgen deprivation therapy; BRT = brachytherapy.
@ = D’amico risk strata [10].
Two patients experienced Clavien grade I urinary inconti-
nence; one patient experienced each of the following: Clavien
grade IIIb bladder neck contracture, rectourethral fistula, and
leiomyosarcoma.
Figure 2 depicts urinary tract toxicity obtained from IPSS
questionnaires. As expected, IPSS scores increased from a
median of 7 to a median of 23 at 3 months following therapy
(𝑝 < 0.0001). Median IPSS dropped to 11 at 9 months
(𝑝 = 0.0005). IPSS continued to decrease at 18 months with
a median of 5, which was not significantly different from
baseline (𝑝 = 0.294).
Two of 21 (9.6%) patients developed de novo urinary
incontinence, and 1 of 21 (4.8%) developed a rectourethral
fistula. One of 21 (4.8%) patients developed bladder out-
let obstruction secondary to fibrosis, requiring endoscopic
correction (transurethral incision of bladder neck). One
patient developed a leiomyosarcoma that ultimately required
cystoprostatectomy but had biochemical control of prostate
cancer.
Table 3 summarizes changes in sexual function during
the study. Eleven of 21 (52.3%) patients had sufficient data
to compare pre- and posttherapy sexual function. Six of
11 (54.5%) patients had stable sexual function, and 5 of 11
(45.5%) had decreased sexual function.
0
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Figure 2: IPSS scores throughout follow-up after salvage
brachytherapy.
3.2. Time to Failure. Themean decrease in PSAwas 4.5 ng/dL
(median 3.4, range 0.3–15.0) after salvage brachytherapy.
At the time of analysis, 11 of 21 (52.4%) patients had not
experienced biochemical recurrence with a mean follow-up
of 61 months. Figure 3 shows a Kaplan-Meier curve for time
Prostate Cancer 5
Table 2: PSA dynamics.
Patient #
Age at initial
treatment
(yrs)
Time between 1st and
2nd Brachytherapy
(mo)
Pre-salvage PSA
(ng/mL)
Presalvage PSA
(ng/dL)
Follow-up
(mo)
Time to nadir
(mo)
1 57 38 6.3 3.6 149 21
2 61 32 5.3 3.6 132 31
3 65 26 4.5 4.4 86 73
4 63 34 10 2.5 111 6
5 59 26 4.9 2.7 119 10
6 50 67 8 14.9 83 10
7 48 287 x 8.6 34 22
8 60 123 7.2 17.41 10 9
9 55 120 6.3 1.53 67 7
10 57 19 5.3 3.49 49 48
11 48 25 6.93 2.77 41 41
12 66 4 4.7 1.86 15 4
13 44 31 8.7 2.41 41 29
14 50 87 7.4 7.3 39 33
15 66 42 19.1 1.68 52 9
16 71 45 6.4 3.11 40 5
17 63 48 8.2 13.8 49 3
18 42 50 1 0.98 40 41
19 58 105 x 11.58 52 17
20 59 48 5.7 4.24 25 7
21 72 21 5.8 3.1 21 15
Mean 57.8 62.9 6.9 5.5 61.4 20.9
Median 59.0 45.0 6.3 3.5 49.0 15.0
SD 8.4 60.2 3.5 4.9 37.9 18.3
𝑛 21 21 19 21 21 21
x = data point not known.
to biochemical recurrence based on initial risk category. For
the men that failed a second brachytherapy procedure, the
median time to failure was 25 months, with a range of 11
to 71 months. There was a trend towards increased time to
biochemical failure in the low risk group compared to the
intermediate risk group (47 months versus 27 months, 𝑝 =
0.12).
4. Discussion
Prostate cancer patients who experience biochemical failure
after initial radiotherapy have a number of options for
subsequent treatment: observation, androgen deprivation
therapy, salvage radical prostatectomy, salvage cryotherapy,
high-intensity focused ultrasound (HIFU), and additional
radiotherapy. Salvage therapy is extremely important to
control locally recurrent disease and prevent metastases, as
lack of further treatment after biochemical recurrence is
correlated with the development of clinical disease within 5
years in up to 75% of patients [11].
Biochemical disease-free survival rates of 55–61% at
5-year follow-up have been reported with salvage radical
prostatectomy.These were relatively small series with 42, 100,
and 138 patients [12–14]. Surgical intervention is even able to
achieve a 51% disease-free survival rate at 5-year follow-up in
patients with a Gleason score of 8 or higher [15, 16]. However,
there are a number of drawbacks to this technique as well.
It can be a technically challenging procedure due to residual
irradiated tissue damage with increased risk of a number
of major complications. Up to 40% of patients are afflicted
with urinary incontinence and 25% suffer from bladder neck
stricture following this intervention [17]. The risk of rectal
injury is 2–9% and urinary fistula is <4% [18].
On the other hand, salvage cryotherapy after initial
radiation is a minimally invasive option with improved
efficacy, especially following the development of modern
techniques to combat issues such as incomplete freezing of
tissue. One study reported biochemical disease-free survival,
defined as PSA <0.5 ng/mL, at 73% for low risk patients,
45% for intermediate risk patients, and 11% for high risk
patients after a median 33.5-months follow-up and actuarial
projection of 60 months [19]. Salvage cryotherapy may be a
less challenging procedure to perform than salvage radical
prostatectomy, giving it minimal variation in outcome across
6 Prostate Cancer
Table 3: Erectile function.
Patient # Age (yrs) Baseline ED 18mo f/u
1 57 1 2
2 61 1 2
3 65 1 3
4 63 1 2
5 59 2 x
6 50 3 x
7 48 1 1
8 60 1 2
9 55 3 x
10 57 x x
11 48 x x
12 66 2 2
13 44 2 2
14 50 3 3
15 66 x 2
16 71 2 x
17 63 3 x
18 42 3 3
19 58 2 2
20 59 3 x
21 72 1 x
1 = no difficulty with erection.
2 = erectile function, but not significant enough for penetration.
3 = impotent.
x represents missing data.
Low risk
Intermediate risk
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Figure 3: Effect of initial risk category on risk of biochemical
recurrence.
health providers [20]. In addition, the reported rates of
complication are low enough to make it an attractive option
for older patients, with urinary incontinence affecting less
than 10% of patients [20, 21]. Cryosurgical ablation of the
whole prostate gland has also been strongly associated with
impotence. Focal cryoablation techniques may limit this
adverse effect by relying on targeted image-guided biopsy
to guide therapy towards undertreated areas or areas of
recurrence, decreasing morbidity [22].
Salvage HIFU has also been studied as a treatment for
locally recurrent prostate cancer following external beam
radiation therapy (EBRT) only. In a study of 167 European
patients, the biochemical disease-free survival was 53%,
42%, and 25% for low, intermediate, and high risk patients,
respectively [23]. While the rate of metastatic disease devel-
opment in this cohort of patients was comparable to that
seen in patients treated with other salvage therapies, the
complication rate was remarkably low, especially with regard
to urinary incontinence and bladder outlet obstruction.
Another European study showed that the rate of bladder
outlet obstruction decreased from 30% to 15% while the rate
of surgical intervention for urinary incontinence decreased
from 15% to 5% [24]. Salvage HIFU, however, is not recom-
mended for patients who had initial brachytherapy due to the
reflective capacity of the implants, which can redirect excess
energy onto surrounding structure such as the rectum and
urethra [25].
In recent years, single center brachytherapy studies have
shown up to 75% biochemical disease-free survival at 4 years
with permanent brachytherapy [17, 26]. In low risk patients
who underwent EBRT alone, one recent study showed a
biochemical disease control percentage of 85.6% after 5 years
[27]. High dose rate (HDR) brachytherapy is now being
used as a more customizable form of dosage for patients
[28, 29]. However, these doses could cause further toxicity to
irradiated damaged tissue and were found in two studies to
cause grade 2 urethral strictures in 71% of patients [28, 30].
One prospective study that usedMRI-guided seed placement
rather than TRUS guidance found that this method was able
to keep the incidence of gastrointestinal and genitourinary
toxicity requiring surgical treatment at 15% in 4 years [17].
They also found that toxicity was decreased in men who had
longer than 4.5-year interval between radiation therapies.
Data on salvage brachytherapy following primary brachy-
therapy, however, is limited. Studies usually mix patients that
were treated with primary brachytherapy with those who
initially underwent EBRT. One study from 1990 reported
outcomes of salvage brachytherapy seed implantation in 13
patients after initial brachytherapy treatment [31]. Recurrence
in this study was detected by digital rectal examination and
confirmed with prostate biopsy. A study by Grimm et al. [32]
showed that of 31 patients who were reimplanted with seeds
for salvage brachytherapy after initial brachytherapy, 87%had
biochemical disease control at 31 months using the ASTRO
criteria. Interestingly, all but one of these patients underwent
3 months of ADT at the time of salvage brachytherapy.
Twenty of 31 (64.5%) of these patients had local recurrence
within the prostate, and 11of 31 (35.5%) had disease within the
seminal vesicles. Eleven of 31 (35.5%) patients were treated
with salvage therapy within 24 months of their primary
therapy, and 20 of 31 (64.5%) were treated more than 24
months after their initial therapy. In light of these results,
treatment of local recurrence of prostate cancer after initial
brachytherapy is an area of evolving interest.
In our series, we show 52.4% freedom from biochemical
recurrence with a mean follow-up of 61 months. These data
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are not as efficacious as those in the Koutrouvelis series,
perhaps due to the longer follow-up in our series. It is also
possible that 3 months of ADT with salvage brachytherapy
led to their superior results, though, in our small subset of
patients who received ADT with their salvage therapy, two-
thirds of patients had biochemical recurrence during our
study. Alternatively, this finding in our study could be due
to a selection bias by the treating physician based on the
individual patients’ risk factors.
When it comes to selecting any salvage therapy modality,
accurately characterizing the presence, location, and extent
of cancer recurrence in an individual is paramount. Improved
cancer targeting and staging techniques significantly improve
the risk-benefit ratio for patients with low and intermediate
risk disease by allowing physicians to remove malignancy
while preserving as much normal tissue and anatomy as
possible [33]. In one study, however, the widely used 12-core
TRUS biopsy technique was only able to predict unilateral
prostate cancer in less than 30% of cases, making it less effec-
tive at choosing patients for focal therapy [34]. Instead, using
a transperineal template-guided mapping biopsy (TTMB)
technique provides better access to the apical and anterior
portions of the prostate where up to one-third of significant
cancer is located [35, 36]. A recent study used TTMB with
multiparametric MRI to assess their combined ability to
detect clinically significant cancer, defined as Gleason 6 with
tumor length over 3mm and any Gleason 7 and above
[37]. The result of the combined testing was a positive
predictive value of 83% and negative predictive value of 91%,
which reliably demonstrates the ability to rule out clinically
significant prostate cancer [37]. In light of a rising PSA, the
negative predictive value of these additional criteria would
be helpful in focusing salvage therapy towards patients with
clinically significant disease [38].
Alternatively, metabolic imaging offers a less invasive
method of detection of both localized and systemic tumor
burden. The available literature varies with regard to the
optimal PSA value at which to initiate 18F-Choline PET/CT
imaging, but there appears to be a strong correlation between
increasing PSA values and the positive predictive ability of
this tool [39]. In one study of 250 prostate cancer patients
with biochemical recurrence, 18F-Choline PET/CT showed
77% sensitivity for cancer detection at a PSA level greater than
0.3 ng/mL and had a particularly high sensitivity in patients
treated with ADT as compared to those who did not receive
ADT [40].
Our study has several key limitations that warrant dis-
cussion. It is a retrospective, nonrandomized study with
inherent selection and treatment biases. Patients were treated
with salvage therapy based on biochemical recurrence alone,
analogous to the delivery of salvage external radiation therapy
for a recurrence following a radical prostatectomy.Therefore,
the majority of patients did not undergo TTMB or repeat
TRUS biopsy prior to salvage therapy, leaving the possibility
that their pathology was different from that of their original
prostate biopsy and skewing their presalvage risk stratifica-
tion. Follow-up was not standardized, leading to incomplete
data on erectile function, lower urinary tract symptoms,
and GI toxicity. Finally, while all patients underwent pri-
mary brachytherapy prior to their salvage brachytherapy, the
cohort remains somewhat heterogeneous.Three of 21 (14.3%)
patients underwent EBRT with their primary brachytherapy.
Seven of 21 (33.3%) patients had ADT with primary therapy
and 3 of 21 (14.3%) hadADTwith their salvage brachytherapy.
One of 21 (4.7%) patients had open brachytherapy seed
placement as initial treatment.
Salvage brachytherapy is an intriguing treatment option
for patients with biochemically recurrent prostate cancer
who underwent primary brachytherapy. In our study, this
modality appears to provide adequate prostate cancer control
in select men with underseeded areas on cross-sectional
imaging. There is a trend towards decreased efficacy of
salvage brachytherapy in patients who were intermediate risk
at initial presentation. Side effects of treatment are higher
than expected with a single brachytherapy implantation;
out of 21 patients 3 individuals developed grade 3 toxici-
ties. The majority of lower urinary tract symptoms resolve
within 9 months of treatment and minimal gastrointestinal
side effects. Further studies are warranted to compare this
treatment modality to other salvage therapies in patients
who underwent primary brachytherapy. Further studies
would perhaps be made more meaningful by utilizing more
advanced methods to evaluate for location of the recurrence
within or beyond the prostate. Technologies have emerged
whichmay be beneficial in better selecting patients for salvage
brachytherapy. For example, methods such as transperineal
mapping,multiparametricMRI, and/or 18F-Choline PET/CT
scans may make partial prostate implants more successful
by better localization of the recurrent disease. However, we
are unaware of any of these new technologies being used to
select patients for salvage prostate brachytherapy. Metabolic
imaging using PET/CT likely will increase the detection of
metastatic prostate cancer [41] thereby better selecting a
population that could benefit from the added brachytherapy
procedure.
Abbreviations
CT: Computed tomography scan
PSA: Prostate-specific antigen
TRUS: Transrectal ultrasound
IPSS: International Prostate Symptom Score
EBRT: External beam radiation therapy
HIFU: High-intensity focused ultrasound
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MRI: Magnetic resonance imaging
HDR: High dose rate
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TTMB: Transperineal template-guided mapping biopsy.
Additional Points
In this project, the authors describe the eleven years of expe-
riences at a single institution of salvage therapy in prostate
cancer patients with biochemical failure and no evidence
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of metastatic disease after interstitial brachytherapy. Images
from the CT scans were evaluated by radiation oncology
and urology faculty. Patients with underseeded areas on
the CT images were considered for reimplantation with I-
125 interstitial brachytherapy; 21 patients were reimplanted.
Our results indicated that the salvage brachytherapy to
underseeded areas after primary brachytherapy in patients
with biochemical recurrence can be a successful procedure.
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